Abbott Laboratories (ABT) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $194.98B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Robert Ford |
| IPO Date | 1980-03-17 | CAGR | 6.66% |
| Employees | 115,000 | Website | www.abbott.com |
| Div. Yield | 0.58% | Payout Ratio | 67% |
| Buy Back Yield | 0.11% | Total Yield | 0.69% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $179.52B | P/E | 21.63 | Forward P/E | 18.58 | PEG | -0.75 |
| P/S | 16.45 | P/B | 14.21 | P/CF | 78.5 | P/FCF | 100.35 |
| Sales | $46.59B | Sales 1Y | 8.06% | Sales 3Y | 15.81% | Sales 5Y | 15.79% |
| EPS | $5.21 | EPS 1Y | -61.02% | EPS 3Y | 6.14% | EPS 5Y | -12.64% |
| Sales QoQ | 12.8% | EPS QoQ | -14.52% | Sales QoQ Avg | 3.26% | EPS QoQ Avg | -13.04% |
| Gross Margin | 56.38% | Operating Margin | 18.17% | Profit Margin | 13.91% | ROCE | 8.91% |
| ROA | 6% | ROE | 12% | Altman Z Score | 3.42 | Piotroski Score | 5 |
| Current Ratio | 1.39 | Quick Ratio | 1.01 | Cash Ratio | 0.37 | Op. CF Ratio | 0.07 |
| Debt/Equity | 0.65 | Debt/Assets | 0.31 | Lt Debt/Equity | 0.57 | Lt Debt/Cap. | 0.36 |
| Intrst Cov. | 23.24 | Inventory Turnover | 2.82 | Asset Turnover | 0.41 | Receivables Turnover | 5.5 |
| Enterprise Value | $179.52B | P/E Ratio | 21.63 |
| Forward P/E | 18.58 | PEG Ratio | -0.75 |
| P/S Ratio | 16.45 | P/B Ratio | 14.21 |
| P/CF Ratio | 78.5 | P/FCF Ratio | 100.35 |
| EPS | $5.21 | EPS Growth 1Y | -61.02% |
| EPS Growth 3Y | 6.14% | EPS Growth 5Y | -12.64% |
| Revenue Growth 1Y | 8.06% | Gross Margin | 0.56% |
| Operating Margin | 0.18% | Profit Margin | 0.14% |
| ROE | 0.12% | ROA | 0.06% |
| ROCE | 0.09% | Current Ratio | 1.39 |
| Quick Ratio | 1.01 | Cash Ratio | 0.37 |
| Debt/Equity | 0.65 | Interest Coverage | 23.24 |
| Altman Z Score | 3.42 | Piotroski Score | 5 |
Abbott Laboratories (ABT) valuation & financials
Abbott Laboratories (ABT) has a market capitalization of $194.98B and trades at a price-to-earnings ratio of 21.6. It operates in the Healthcare sector (Medical - Devices).
Abbott Laboratories's revenue grew +8.1% over the last year.
Abbott Laboratories's next earnings report is scheduled for October 21, 2026; analysts estimate EPS of $1.42. Check the earnings calendar to see all companies reporting this week.
Abbott Laboratories (ABT) — frequently asked questions
When does Abbott Laboratories (ABT) report earnings next?
Abbott Laboratories is expected to report earnings on October 21, 2026. Analysts estimate EPS of $1.42.
What is Abbott Laboratories's market cap?
Abbott Laboratories (ABT) has a market capitalization of $194.98B.
What is ABT's P/E ratio?
Abbott Laboratories trades at a price-to-earnings ratio of 21.6, with trailing twelve-month EPS of $5.21.
How fast is Abbott Laboratories growing?
Abbott Laboratories's revenue grew +8.1% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)